>> Interesting snippet from today's CRGN PR <<
1. If you inject human proteins into a normal mouse, you often get antibodies, just as you do when you stick mouse proteins into man. I'm not saying that it can't be done. I'm just siding with CAT et al. If I were out there, today and targeting a human protein, I'd be working with every model available.
2. Serology..... immunoglobulins have made it into clinical trials that had nothing to do with the disease that they were targeting. IMO, at least two made it through to rather large, pivotal-like trials. Take initial claims with skepticism.
Publications would roll out of academic labs, and they're not going to have the sort of brute strength capacities that ABGX/CRGN can press into action. Anti-bacterial, anti-toxin, anti-viral, etc.? They shouldn't require as much brute force, IMO. So maybe the lack of publications isn't truly something to worry about. Perhaps it just reflects a barrier to effective entry which can be used to judge ABGX versus MEDX.
I'm too far out of the loop to comment further. Perhaps I shouldn't have gone this far. |
